AXIM Biotech: Building a Lower Cost Portfolio of Cannabinoid …

REDONDO BEACH, CA–(Marketwired – Jan 31, 2017) – SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing AXIM® Biotechnologies Inc.’s ( OTCQB : AXIM ) efforts to keep its drug development costs at a minimum.

The average cost of developing a prescription drug is some $2.6 billion, according to the Tufts Center for the Study of Drug Development, which includes $1.4 billion in out-of-pocket costs and an estimated $1.2 billion in returns that investors forego

...read more at http://finance.yahoo.com/news/axim-biotech-building-lower-cost-140000719.html

by